NPS detection in prison: A systematic literature review of use, drug form, and analytical approaches

Giorgia Vaccaro | Anna Massariol | Amira Guirguis | Stewart B. Kirton | Jacqueline L. Stair

Abstract
This paper presents a systematic literature review on the detection of new psychoactive substances (NPS) in prison settings. It includes the most frequently reported NPS classes, the routes and forms used for smuggling, and the methods employed to analyse biological and non-biological samples. The search was carried out using MEDLINE (EBSCO), Scopus (ELSEVIER), PubMed (NCBI), and Web of Science (Clarivate) databases, along with reports from the grey literature in line with the PRISMA-S guidelines. A total of 2708 records were identified, of which 50 met the inclusion criteria. Findings showed the most prevalent NPS class reported in prison was synthetic cannabinoids (SCs). The most frequently reported SCs in non-biological samples were 4F-MDMB-BINACA, MDMB-4en-PINACA, and 5F-ADB. These were smuggled mainly through the postal services deposited on paper or herbal matrices. Concentrations of SCs detected on seized paper ranged between 0.05 and 1.17 mg/cm². The SCs most frequently reported in biological specimens (i.e., urine, blood, saliva, and wastewater) were 5F-MDMB-PICA, 4F-MDMB-BINACA, and MDMB-4en-PINACA. Concentrations of SCs reported in femoral blood and serum were 0.12–0.48 ng/ml and 34–17 ng/ml, respectively. Hyphenated techniques were predominantly employed and generally successful for the detection of NPS in biological (i.e., LC-HRMS/MS) and non-biological samples (i.e., LC-HRMS/MS and GC-MS). The onsite technique IMS showed promise for detecting SCs in various forms; however, immunoassays were not recommended. Future work should focus on accurate in-field detection of SCs deposited on paper and in urine and saliva to improve real-time decision-making, as well as wastewater and air monitoring for overall drug use trends.

Keywords
new psychoactive substances, NPS, prisons, synthetic cannabinoids, systematic literature review
1 | INTRODUCTION

In recent years, the use of new psychoactive substances (NPS) in prison settings has become a cause of concern internationally.\(^1\)–\(^9\) The situation reported by 24 countries including the United Kingdom, Germany, Sweden, Hungary, Latvia, Australia, and the United States\(^1\)–\(^11\) has proven particularly challenging. It has been reported that the use of NPS in prisons has led to increased levels of violence, organized crime, bullying, aggression, and debt.\(^8\)–\(^10\),\(^12\)

Although initial measures including training modules for staff, implementation of mandatory drug testing (MDT), infrastructural changes, and/or legislative restrictions,\(^9\) NPS use in prison remains an issue of major concern.\(^13\) Whilst there is evidence suggesting that the use of NPS worldwide may be declining, this trend is not observed in marginalized groups, including prison populations.\(^14\)

Use has increased among such populations, for example, seizures of NPS in UK prisons have increased from 4560 in 2017 to 9114 in 2021.\(^15\) Thus, timely and collated information focused on the identification of NPS in the prison environment is critical to further understand and ultimately tackle NPS use in this setting.

NPS are defined by the United Nation Office on Drugs and Crime (UNODC) and European Monitoring Centre on Drugs and Drugs Abuse (EMCDDA) as “substances of abuse, either in a pure form or a preparation, that are not controlled by the 1961 Single Convention on Narcotic Drugs or the 1971 Convention on Psychotropic Substances, but which may pose a public health threat.”\(^1\)–\(^16\) In addition, NPS have been associated with public health risks similar to traditional drugs of abuse (TdA), and they have also been shown to induce unpredictable health risks. The World Drug Report 2020 further specifies that “the term ‘new’ does not necessarily refer to new inventions, but to substances that have recently become available.”\(^1\)–\(^16\) Due to the structural diversity of NPS, they are largely classified according to their substance groups, for example, aminoindanes, phenylcyclohexamine-type substances, phenethylamines, piperazines, plant-based substances, synthetic cannabinoids (SCs), synthetic cathinones, tryptamines, and “other” substances such as designer opioids and benzodiazepines.\(^1\)–\(^16\)

The use of NPS in prisons was first reported in the United Kingdom around 2013\(^17\) and in the years to follow in other European and non-European countries.\(^9\) These compounds represented a valid alternative to TdA because of their low price, ease of availability, and undetectability.\(^2\)–\(^3\),\(^7\)–\(^10\) In addition, high potency NPS, for example, SCs, are popular amongst prisoners as the desired effect can be achieved with a lesser amount of substance and hence for a cheaper price.\(^1\)–\(^8\),\(^18\) In particular, SCs are used in this environment to aid in coping with imprisonment, sustaining existing habits, and for self-medication or pleasure.\(^6\) Until a few years ago NPS in the United Kingdom were not normally screened in routine MDT,\(^19\) making them an attractive alternative to TdA. Despite that some NPS are now included in MDT, their structures are continuously being altered by producers to avoid detection.\(^19\)

The market availability of specific NPS is strictly connected to countries’ respective legislation in place at the time of production and/or consumption.\(^20\),\(^21\) This results in a constantly evolving market of NPS which presents the main analytical challenge for in-field instruments and laboratories in charge to detect and quantify these substances. The large number of structurally diverse NPS available (\(\sim950\) registered by UNODC\(^22\) and \(>4200\) on the web\(^23\)), and the pace at which these appear on the market (one new NPS per week\(^26\)) are also contributing factors challenging detection, due to a lag in certified reference standard (RS) availability.\(^2\),\(^3\) Low concentrations of potent NPS, for example, SCs or opioids, combined with inhomogeneous distribution on new matrices or formulations, employed to facilitate smuggling in prisons, are also factors making difficult their detection and identification.\(^25\)

Currently, there are no universal globally agreed standard operating procedures (SOP) in place to identify TdA as well as NPS in prison. Drugs of abuse are often confiscated in this setting via cell, inmate, or visitor searches performed by prison officers.\(^26\) In some countries, such as the United Kingdom, the United States, and Canada, the use of sniffer dogs has also been reported for detection of TdA\(^26\) as well as SCs.\(^25\),\(^27\) However, due to the ever-changing nature of the NPS market, it is difficult to maintain the long-term effectiveness of sniffer dogs with these substances.\(^9\) Once samples suspected to contain drugs are identified, these are screened using in-field analytical techniques such as ion mobility spectrometry (IMS)\(^28\) and/or sent to external forensic laboratories for confirmatory analysis. External forensic laboratories employ traditional analytical techniques such as gas chromatography–mass spectrometry (GC–MS), liquid chromatography–mass spectrometry (LC–MS), and nuclear magnetic resonance (NMR), which are costly and time consuming,\(^29\) but can give meaningful information even in the absence of RS. In addition, drug use can be identified by analysis of prisoners’ biological specimens,\(^26\) which are also commonly sent to external forensic laboratories for analysis.

The aim of this manuscript is to investigate the current state of chemical detection and identification of NPS in prisons based on the available literature, looking at (I) the most predominant groups and specific NPS which have been reported in prison; (II) the routes and forms through which these were smuggled into prison, and (III) the analytical methods employed to detect and identify NPS in biological and non-biological samples from prisons. A particular focus will be given to the UK situation for points (I) and (II). Recommendations are then presented in the future works section based on the findings of this review. To the best of the authors’ knowledge, this marks the first systematic literature review examining detection in the prison setting for this complex and emerging group of substances.

2 | METHODOLOGY

The methodology has been developed in line with the Preferred Reporting Items for Systematic reviews and Meta-Analyses literature search extension (PRISMA-S),\(^30\) which is a checklist employed to ensure that each component of a systematic literature search is completely reported, hence reproducible. Search words belonging to group 1 (including keywords such as NPS, NPS classes, and their...
3.1 An overview of NPS reported in prisons

In order to have effective detection approaches, the NPS prisons' scene should be evaluated. This section provides an overview of NPS reported in the prison setting to date, based on the available resources. A variety of sources were identified including quantitative/qualitative self-reporting studies, analytical studies of biological/non-biological samples, organizational reports, and generic publications on NPS in prison. These were used to establish the NPS groups, as well as the specific compounds reported in prisons. Although some of the studies may be different in nature, the information on the NPS group or the specific name was collated to highlight overall observed trends in the literature. The number of publications related to NPS found in prison settings from 1978–2020 has increased from approximately 2010 to the present (Figure S1). No articles were found prior to 1978, and those found after 2010 mostly refer to the newly reported psychoactive substance phenomena. Most of the articles were quantitative/qualitative self-reporting studies or generic publications on the topic; however, since 2017, interest in the chemical analysis of NPS seized in prisons has increased. For example, approximately 18% (n = 2) of the articles published in 2019 had an analytical perspective which increased to almost 38% (n = 6) in 2020. Overall, the increasing number of publications demonstrates the growing interest in this topic.

An overview of the types of NPS reported in prisons is shown in Table 1. The NPS substance groups, reported in order of prevalence, were SCs, synthetic cathinones, synthetic opioids, benzodiazepines, stimulants, piperazines, and plant-based substances. The predominant group of NPS that have been reported in prison were SCs, with a total of 63 different SCs and/or their metabolites. Due to the large number of SCs reported, this specific group was further divided into the nine relevant subgroups of alkoylindoles, benzoylindoles, carboxazoles, γ-carbolines, indole carboxylates, indole carboxamides, indazole carboxamides, naphthoylindoles, and 7-azaindole carboxamides. The carboxamides were further divided into adamanely, cumylamine, valinamide, valinate, tert-leucinamide, and tert-valinate derived groups (Table 1). The most frequently referenced SCs were 4F-MDMB-BINACA (aka 4F-MDMB-BUTINACA), 21,32,34,36,38-40,47 5F-MDMB-PICA, 5,9,19,31,33,37,38,42,43,47,48,63,64,70 5F-ADB (aka 5F-MDMB-PINACA), 4,5,21,28,33,34,38,39,45 AB-CHMINACA, 4,19,21,28,31,42 AMB-FUBINACA (aka FUB-AMB, MMB-FUBINACA), 5,5,21,25,28,38 and MDMB-CHMICAC 21,27,31,33,42,43 (Figure 2). These all belong to the indazole and indole carboxamide subgroups of tert-leucinamide, tert-leucinate, valinamide, and valinate derived. The majority of studies were reported by Germany, the United Kingdom, and the United States. The availability of specific SCs is connected to the legislation related to their production, import, and export countries. 20 For instance, when the People’s Republic of China in 2018 placed under control 32 NPS, including 5F-ADB, ADB-FUBINACA, and AMB-FUBINACA, a reduction in findings of these substances was registered across different countries. 21,38 A year later new SCs, structurally related to the latter but not covered by the legislative control, for example, MDMB-4en-PINACA and 4F-MDMB-BINACA, made their
This highlights the evolving nature of the SC market, where trends are also reflected in the prison drug market. An example of the evolving SC market is related to the current loss of popularity of 5F-PB-22, which emerged and peaked from 2013 to 2015 in the United States and English prisons. The disappearance of 5F-PB-22 from the market was again due to its placement under control by the People’s Republic of China in October 2015. Table 1 also identifies less common yet more recent SCs. In January 2019 in Germany, the \( \gamma \)-carbolines derived 5F-cumyl-PEGACLONE was found for the first time in the post-mortem blood and urine of a prisoner. The same SC was later found also in urine from German prisons along with cumyl-CBMEGACLONE and cumyl-PEGACLONE, also belonging to the \( \gamma \)-carbolines. Other newly emerging SCs belonging to the subgroup 7-azaindole carboxamides were 5F-MDMB-P7AICA and cumyl-4CN-B7AICA, also detected for the first time by urinalysis in German prisons in 2021.

SCs were also often reported in general studies but referred to by their street name “Spice”; these studies are collated under the “non-specific” subgroup in Table 1. A high level of self-reported use of SCs in England was documented by the “Spice awareness project” (unpublished work) undertaken in a category C prison in November 2014, by a charity. It reported that 80% of prisoners tried “Spice” during their current sentence, while around 65% admitted to using “Spice” currently. Similar results were found in a report published in May 2016, which surveyed 684 prisoners across nine English prisons. It found that 33% of prisoners reported having used “Spice” in the last
| NPS group, subgroup and name | Country | Reference |
|----------------------------|---------|-----------|
| **SYNTHETIC CANNABINOIDS** |         |           |
| Alkoylindoles              |         |           |
| 5F-UR-144                  | England | 31        |
| FUB 144 (aka FUB-UR-144)    | Germany | 21        |
| UR-144                     | England | 31        |
| **Benzoylindoles**         |         |           |
| AM-694                     | England | 31        |
| **Carbazoles**             |         |           |
| EG-018                     | Germany | 21        |
| **γ-Carbolines**           |         |           |
| 5F-cumyl-PEGACLONE         | Germany | 21,32     |
| Cumyl-CBMegaClone          | Germany | 21        |
| Cumyl-PegaClone            | Germany | 21,28     |
| **Indole Carboxylates**    |         |           |
| 5F-PB-22                   | England, Wales | 21,31,33 |
| PB-22 (aka QUPIC)          | England, Germany, Scotland | 28,31,34 |
| QUCHIC (aka BB-22)         | England | 31        |
| **Indole Carboxamides**    |         |           |
| 5F-MPP-PICA                | Scotland | 21,34    |
| FUB-PB-22 (aka QUFBIC)     | England | 31        |
| **(a) Adamantly derived**  |         |           |
| STS-135 (aka 5F-APICA)     | England | 31,35     |
| **(b) Cumylamine derived** |         |           |
| 5F-cumyl-PICA              | Germany | 21        |
| Cumyl-CBMICA               | Germany | 21        |
| **(c) Valinate derived**   |         |           |
| 5F-EMB-PICA (aka EMB-2201) | Scotland | 21,34,36,37 |
| AMB-4en-PICA (aka MMB-4 en-PICA) | Germany | 21 |
| AMB-FUBICA                 | Germany | 21        |
| MMB-2201                   | Germany | 28        |
| MMB-CHMICA (aka AMB-CHMICA) | England, Scotland, USA | 5,21,25,31,34,38 |
| **(d) Tert-leucinamide derived** |         |           |
| 5F-ABICA                   | Germany | 21        |
| **(e) Tert-leucinate derived** |       |           |
| 4F-MDBB-BICA               | Belgium, Cyprus, France, Hungary, Lithuania, Slovenia, UK | 21,34,36,37 |
| 5F-MDBB-PICA               | Germany, UK, USA | 5,9,21,34,36–41 |
| (R)-5F-MDBB-PICA           | Scotland | 20        |
| MDBB-CHMICA                | England, Germany, Wales | 21,27,31,33,42,43 |
| **Indazole Carboxamides**  |         |           |
| THJ-2201                   | England | 31        |
| **(a) Adamantly derived**  |         |           |
| 5F-APINACA (aka 5F-AKB-48)  | England, Wales | 21,27,31,33,35 |
| APINACA (aka AKB-48)        | England, Germany | 21,28,31,35 |
| FUB-APINACA                | Germany | 21        |
| **(b) Cumylamine derived** |         |           |
| 5F-cumyl-PINACA            | England | 31        |
| NPS group, subgroup and name | Country | Reference |
|-----------------------------|---------|-----------|
| Cumyl-4CN-BINACA (aka Cumyl-CYBINACA) | Germany, Lithuania, UK, USA | 5,21,44 |
| Cumyl-CBMINACA | Germany | 21 |
| (c) Valinate derived | | |
| AB-CHMINACA | Germany, Lithuania, UK, USA | 4,19,21,28,31,42 |
| AMB-FUBINACA (aka FUB-AMB, MMB-FUBINACA) | England, Germany, Scotland, Wales, USA | 4,5,21,25,28,38 |
| (d) Valinate derived | | |
| 5F-AMB (aka 5F-MMB-PINACA, 5F-AMB-PINACA) | England, USA | 4,31 |
| (e) Tert-leucinamide derived | | |
| 5F-AB-PINACA | England, Germany | 21,31 |
| 5F-ADB (aka 5F-MDB-PINACA) | Germany, UK, USA | 4,5,21,28,33,38,39,45 |
| (R)-5F-ADB (aka (R)-5F-MDB-PINACA) | Scotland | 20 |
| 5F-ADB-PINACA | England, Germany | 21,31 |
| AB-FUBINACA | England, Germany | 21,27,31,42 |
| ADB-BINACA | Germany | 21 |
| ADB-CHMINACA | Germany | 21,42 |
| ADB-FUBINACA | Germany, USA | 21,42,46 |
| (f) Tert-leucinate derived | | |
| 4F-MDB-BINACA (aka 4F-MDB-BUTINACA) | Germany, Scotland, Wales | 21,32,34,36,38–40,47 |
| (R)-4F-MDB-BINACA | Scotland | 20 |
| MDMB-4en-PINACA | Belgium, Cyprus, France, Germany, Hungary, Lithuania, Slovenia, UK, USA | 34,36–38,48 |
| (R)-MDMB-4en-PINACA | Scotland | 20 |
| MDMB-ChminACA | Germany | 21 |
| MDMB-FUBINACA (aka FUB-MDBMB, MMB-Bz-F) | USA | 4 |
| Naphthoylindoles | | |
| AM-2201 | Germany, England, Norway | 31,42,49 |
| JWH-018 | Norway | 21,49 |
| JWH-081 | Germany | 21 |
| JWH-122 | Germany | 21 |
| JWH-210 | Germany | 21 |
| MAM-2201 | England | 31 |
| 7-Azaindole Carboxamides | | |
| 5F-MDB-P7AICA | Germany | 21 |
| Cumyl-4CN-B7AICA | Germany | 21 |
| Non-Specific (e.g., Spice) | Croatia, Cyprus, Czech Republic, Finland, France, Germany, Hungary, Ireland, Italy, Latvia, Lithuania, Norway, Poland, Slovenia, Sweden, and UK | 6,8–11,17,50–62 |
| SYNTHETIC CATHINONES | | |
| 4F-PHP | Scotland | 38 |
| 4-MEC | England | 31 |
| Mephedrone | Australia, England | 31,63,64 |
| Methylene | Australia | 63 |

(Continues)
month, making it the most popular misused substance amongst hooch (illegally brewed alcohol), cannabis, heroin substitutes, and heroin. Interestingly, around 66% of survey respondents thought that more than half of the prisoners in their prison used “Spice.” In contrast, a survey by Her Majesty Inspectorate of Prisons (HMPI) distributed to inmates in eight prisons between June and November 2014 (n = 1376) reported that only 10% had used “Spice” during their current sentence. The discrepancies in the results of the self-reported studies might be confounded by the differing level of trust prisoners exhibit towards the organizations conducting the studies.

Synthetic cathinones, synthetic opioids, new benzodiazepines, and stimulants were also found. In 2017, 10 European countries reported synthetic cathinones being used in their prisons according to the EMCDDA. Additionally, two subsequent studies reported the detection of mephedrone and 4-methylmethcathinone (4-MEC) in English prisons. Synthetic cathinones were also reported in an Australian wastewater analysis (WWA) study, which identified methylene and mephedrone in a small prison facility. Synthetic opioids were less reported in European prisons in comparison with SCs and cathinones. Studies reporting opioid usage were confined mainly to the North-Eastern area of Europe and in Italy. Specifically, a total of 10 seizures of synthetic opioids were reported from prisons in Latvia, including acryloylfentanyl, carfentanil, and cyclopropylfentanyl. In England, etizolam was identified sprayed onto letters that were seized and analysed in 2015, where up to three SCs, stimulant NPS such as ethylphenidate, methoxphenidine, methiopropamine, and adulerants were also detected. It is not well understood why low potency NPS and adulerants were found in conjunction with SCs in this matrix, and it was not possible to ascertain whether these were intentionally added to achieve enhanced desirable effects or perhaps to hinder identification.

To a lesser extent, substances belonging to the NPS groups of piperazines, plant-based, and phencyclidine-type have also been reported in prison settings. For example, the NPS 1-benzylpiperazine was detected in Sweden between 2000 and 2002 in 11 post-mortem biological samples. In some of the analysed specimens, traces of amphetamines were also found. It was unclear whether the prisoners intended to take the piperazine analogue or believed that it was amphetamine. Kava (Piper methysticum) is a plant that grows in the South Pacific Islands with both stimulant and depressant effects on the central nervous system (CNS); its kavalactone, dihydrokavain, was found in three pre-release and one voluntary drug testing (VDT) urine specimens in a prison near Manchester (UK) in 2015. A thematic report by HMPI suggests that despite some differences, drug use in

### TABLE 1 (Continued)

| NPS group, subgroup and name | Country | Reference |
|-----------------------------|---------|-----------|
| Non-Specific                | Cyprus, Czech Republic, Finland, France, Germany, Hungary, Latvia, Lithuania, Poland, Sweden | 9 |

### OPPIOIDS

- Acryloylfentanyl: Latvia (65)
- Carfentanil: Latvia (66)
- Cyclopropylfentanyl: Latvia (67)
- Non-Specific: Czech Republic, Finland, Italy, Latvia, Poland (9)

### STIMULANTS

- 4-methylmethamphetamine: England (31)
- Ethylphenidate: England (27,31)
- Methylhexaneamine: England (27,31)
- Methiopropamine: England (27,31)

### BENZODIAZEPINES

- Etizolam: England (27)
- Non-Specific: Finland, Italy, Latvia, Poland (9)

### PIPERAZINES

- 1-benzylpiperazine: Sweden (68)

### PLANT-BASED

- Dihydrokavain: England (31)

### PHENCYCLIDINE-TYPE

- Methoxphenidine: England (27)

---

*The NPS groups were adapted from UNODC Word Drug Report 2020. The NPS subgroups were adapted from Abate et al. Includes the NPS and its metabolites.
prison reflects, to some extent, the use in the general population. Generally, in both prison and the general population, drugs with a depressant effect on the CNS are preferred over their stimulant counterparts. Yet, higher use of stimulants in the general population is suggested by Bonds and Hudson (2015) where the results of urinalysis showed a 3.5-fold increase in stimulant detection for prisoner admission ("on reception" samples) versus incarcerated residents ("pre-release," MDT and VDT samples). Despite the latter study took place in 2015, it is the only study available reporting data on different NPS classes, including stimulants, in the prison setting. The results from Table 1, including literature/reports outside of the United Kingdom, also follow an NPS prison trend favouring SCs, used to relieve stress and boredom of imprisonment.

3.2 NPS smuggling routes and forms

Knowledge of potential smuggling routes and forms, which may differ from that of TdA, could help inform and support the prison security system in tackling detection and identification of NPS. A total of 26 studies related to NPS smuggling routes and forms, employed to illegally introduce NPS in prisons, were retrieved from the literature.
Seventeen out of 26 studies applied to the NPS smuggling routes employed in prisons and were divided into seven groups (Figure 52). The postal service was highlighted as the most prevalent smuggling route \((n = 14)\) for bringing NPS into prisons through parcels or mail.\(^8\) Due to the trend of spraying NPS on paper, some UK prisons photocopied prisoners’ correspondence, which reduced smuggling but was time-consuming. However, in some circumstances (e.g., English and Welsh prison “Rule 39” and Scotland “Legal Mail”) legal, confidential correspondence can only be opened and inspected by prison staff in specific situations, which makes photocopying and routine checks more complicated.\(^76\) The second most reported NPS smuggling routes, each described in five articles, were concealment inside the body and transportation over prison walls. Concealment in body orifices,\(^6,9,10,46,60\) for example, gastrointestinal system, rectum, or vagina, is particularly challenging to detect;\(^72\) new prisoners were found to smuggle up to 280 g of SCs through this route.\(^10\) X-ray body scanners able to detect drugs concealed inside the body or under clothes are being introduced in more UK prisons to tackle the issue. Transportation over prison walls was also reported via drones,\(^6,8–10,46,76\) or using catapults.\(^8\) NPS thrown over the wall were found to be concealed also in unusual items, such as carcasses of birds\(^6,9\) or oranges.\(^9\) To overcome this issue, some prisons installed nets around the perimeters or used radar systems to intercept drones. Lesser reported NPS smuggling routes included via new prisoners or prisoners who were released on bail,\(^5,9,10\) prison staff,\(^6,8,10\) visitors,\(^8–10\) and external contractors\(^9\) including cleaning companies, waste disposal trucks, and canteen distributors.

Twenty-five studies applied to the forms in which NPS are smuggled into prison. The forms reported for NPS in prison (Figure S3) were via paper matrices, herbal mixtures, food and drinks, solid materials, clothes, cosmetics, and e-liquids. Paper matrices \((n = 19)\), commonly delivered by postal services or during social visits, were the main form reported that was used to smuggle NPS\(^6,9,10,12,47,59–61,77\) as confirmed by analytical studies performed on seized samples.\(^5,20,21,25,27,28,34,38,41\) The term “paper matrices” is used to encompass letters, children’s drawings, blank paper sheets, greeting cards, photographs, books, documents, poems, blotters, paper snippets, Bible pages, online printed catalogues, rice paper, crosswords, and sudoku puzzles.\(^5,6,9,10,12,20,21,25,27,28,34,38,41,47,59–61,77,78\) Prisoners are believed to take NPS, specifically SCs, by licking, chewing, swallowing, smoking, or placing in eyes;\(^21\) the paper, which is usually cut into 1 cm\(^2\) or smaller pieces.\(^26\) When in this formulation and size, such samples are easily concealed, carried, and traded between inmates.\(^38\) SCs are commonly produced in solid form, then dissolved in an organic solvent such as acetone, and easily sprayed onto paper matrices\(^10\) or herbal material.\(^31\) Recently, other general reports also highlight paper matrices as the most popular form to smuggle NPS in prison across Europe, especially in Finland, Germany, Hungary, Lithuania, Poland, and Sweden.\(^5,6\) because of the challenges in detection.\(^8\) The second most prevalent form reported was herbal mixtures\(^21,28,31,38,45,46,66,77\) \((n = 8)\). In particular, herbal/plant material such as marshmallow \((Althea officinalis)\) leaves\(^31\) or tobacco\(^28,64\) were mixed or sprayed with SCs. In UK prisons, inmates were found smoking cigarettes laced with SCs infused herbs,\(^38\) yet after the smoking ban was implemented (2018), NPS were found infused in paper inserted between the heating constituent and the cartridge of e-cigarettes.\(^21\) The increased risk of fatal and non-fatal overdoses, related to the consumption of SCs in the forms discussed, could also be due to their heterogeneous distribution on the matrices.\(^31\) Areas with a high drug concentration on paper are known as “hot-spots,”\(^9\) while those on herbal mixtures are known as “hot-pockets.”\(^79\) Moreover, this has implications for chemical detection, making representative sampling by the analyst challenging.\(^31,38\) Apirakkan et al. determined analytically the presence of SCs dissolved in vaping liquid,\(^25\) purchased from internet retailers before the 2016 UK “legal high ban.” In 2021, SCs in vaping liquid were also found in Welsh prisons, accounting for only 0.6% of SC samples analysed\(^31\); however, the popularity of this new formulation could grow due to detection difficulty and will require monitoring in the future. NPS were also found in the lid of soft drinks\(^10\) and in the form of pre-sealed food packages such as crackers, coffee, and instant noodles.\(^9\) SCs were also seized in solid, powder, and crystalline forms\(^21,31,67\) as well as found sprayed on clothing,\(^60\) and textiles,\(^28\) in prison settings. Lastly, acryloylfentanyl, a new synthetic opioid, was detected in a cosmetic cream in a Latvian prison.\(^65\)

### 3.3 NPS detected in non-biological and biological prison samples

The studies in which NPS were detected in non-biological and biological samples from prisons are summarized in Tables 2 and 3, respectively. SCs were the most reported group of NPS in both samples matrices.\(^4,5,20,21,31,32,34,35,38,40,41,43,46,48,49\) Based on the results of our review, 5F-APINACA (aka 5F-AKB-48) (337 findings), 4F-MDMB-BINACA (aka 4F-MDMB-BUTINACA) (273 findings), 5F-PB-22 (273 findings), MDMB-4en-PINACA (246 findings), 5F-MDMB-PICA (141 findings), and 5F-ADB (aka 5F-MDMB-PINACA) (131 findings) were the most reported NPS in seizures. While the most detected SCs in biological samples were 5F-AKB-48 (1449 findings), MDMB-CHMICA (584 findings), 5F-MDMB-PICA (388 findings), 4F-MDMB-BINACA (301 findings), MDMB-4en-PINACA (166 findings), and AB-FUBINACA (124 findings). The above specific SCs results are skewed by the extensive number of samples analysed in the study carried out by Bonds and Hudson in English prisons, where 39% of seized samples \((n = 1088)\) and 17.9%/16.9% of phase I \((n = 7395)/\text{phase II} (n = 1833)\) urine samples tested positive for SCs.\(^31\) Although this study gives an indication to the extent SCs are used in prisons it is dated back to 2015 and does not necessarily reflect current prison trends on specific SCs. A more recent study by Norman et al. (2021) reported SCs found in prison seizures between 2018 and 2020 in Scotland and Wales.\(^21\) In this study, the most prevalent were 4F-MDMB-BINACA (aka 4F-MDMB-BUTINACA) (244 findings) MDMB-4en-PINACA (209 findings), and 5F-ADB (aka 5F-MDMB-PINACA) (179 findings). The same study also reported a 33.6% incidence of SC detection in urine samples from German prisons\(^21\) of which
5F-MDMB-PICA (376 findings), 4F-MDMB-BINACA (aka 4F-MDMB-BUTINACA) (297 findings), and MDMB-4en-PINACA (165 findings) were the most reported. This study, carried out internationally, showed that some similarities between countries such as Germany, England, Wales, and the United States, were present, for example, high prevalence of 5F-MDMB-PINACA, which are usually driven by

### Table 2
Summary of NPS detected in non-biological prison samples

| NPS detected | Sample form | Analytical technique | Method | Country | Sample's year | Reference |
|--------------|-------------|----------------------|--------|---------|---------------|-----------|
| AMB-FUBINACA and MMB-CHMICA | Paper | UHPLC-MS/Q-Orbitrap | Qualitative | England | N.A. | 25 |
| 5F-AKB-48, AB-FUBINACA, ethylphenidate, etizolam, MDMB-CHMICA, methiopropamin, methylphenidate and methoxphenidine | Paper | UPLC-MS/QToF | Qualitative | England | 2016 | 27 |
| (S) and (R)-4F-MDMB-BINACA, (S) and (R)-5F-MDMB-PICA, (S) and (R)-5F-MDMB-PINACA, (S) and (R)-MDMB-4en-PINACA | Paper | Chiral HPLC-MS/QToF | Qualitative | Scotland | 2018-2020 | 20 |
| 4F-PHP, 4F-MDMB-BINACA, 5F-MDMB-PICA, AMB-CHMICA, AMB-FUBINACA and MDMB-4en-PINACA | Paper | GC-MS; UPLC-MS/QToF and NMR | Quantitative | Scotland | 2018-2019 | 38 |
| 4F-MDMB-BINACA and 5F-MDMB-PICA | Paper | GC-MS and HPLC-MS/QToF | Qualitative | Germany | 2019 | 41 |
| 4F-MDMB-BUTINACA, 4F-MDMB-BUTINACA 2'-indazole isomer, 5F-ADB and 5F-MDMB-PICA | Paper | GC-MS | Qualitative | USA | 2019 | 5 |
| 4F-MDMB-BICA, 4F-MDMB-BINACA, 5F-EMB-PICA, 5F-MDMB-PICA, 5F-MPP-PICA, 5F-MDMB-PINACA, AMB-CHMICA, MDMB-4en-PINACA and PB-22. | Paper | IMS; GC-MS and UPLC-MS/QToF | Qualitative | Scotland | 2018-2020 | 24 |
| 4F-MDMB-BICA, 4F-MDMB-BINACA, 5F-EMB-PICA, 5F-MDMB-PICA, 5F-MPP-PICA, 5F-MDMB-PINACA, AMB-CHMICA, MDMB-4en-PINACA and PB-22. | Paper | GC-MS and UPLC-MS/QToF | Qualitative | Scotland | 2018-2020 | 21 |
| 5F-ADB (5F-MDMB-PINACA), AB-CHMINACA, APINACA, cumyl-PEGaClone, FUB-AMB, MMB-2201 and PB-22 | Herbal mixture, solid, paper, e-liquid | UPLC-MS/QToF | Qualitative | Wales | | |
| 5F-ADB (5F-MDMB-PINACA), AB-CHMINACA, APINACA, cumyl-PEGaClone, FUB-AMB, MMB-2201 and PB-22 | Herbal mixture, paper | IMS and GC-MS | Qualitative | Germany | N.A. | 28 |
| 5F-AKB-48, 5F-AMB, 5F-PB-22, 5F-UR-144, AB-CHMINACA, AB-FUBINACA, AKB-48, AM-2201, FUB PB-22, MAM-2201, MDMB-CHMICA, PB-22, QUCHIC, STS-135 and UR-144 | Herbal mixtures | GC-MS | Qualitative | England | 2014-2015 | 31 |
| 5F-AKB-48, 5F-PB-22, AB-FUBINACA, AKB-48, AM-2201, mephedrone, PB-22 and STS-135 | Herbal mixtures | UPLC-MS/QToF | Qualitative | England | 2014-2015 | 64 |

*aUltra-high performance liquid chromatography-mass spectrometry/quadrupole-orbitrap.
*bUltra-performance liquid chromatography-mass spectrometry/quadrupole time of flight.
*cGas chromatography-mass spectrometry.
*dNuclear magnetic resonance.
*eIon mobility spectrometry.
| NPS detected                                                                 | Sample Form | Analytical technique                          | Method      | Country     | Sample's year | Reference |
|------------------------------------------------------------------------------|-------------|-----------------------------------------------|-------------|-------------|---------------|-----------|
| 4-MEC, 4-methylmethamphetamine, 5F-AB-PINACA, 5F-ADB-PINACA, 5F-AKB-48, 5F-PB-22, 5F-UR-144, AB-CHMINACA, AB-FUBINACA, ADB-FUBINACA, AKB-48, AM-2201, AM-694, cumyl-5F-PINACA, ethylphenidate, FAM-2201, dihydrokavain, mephedrone, methiopropamine, methylhexaneamine, MAM-220, MDMB-CHMICA, STS-135, THJ-018, THJ-2201 and UR-144 | Urine       | UHPLC-MS/LTQ-Orbitrap<sup>a</sup> and UHPLC-MS/Q-Orbitrap | Qualitative | England     | 2014-2015    | 31        |
| SCRAs                                                                         | Urine       | Immunoassay                                   | Qualitative | England     | N.A.          | 35        |
| 3rd generation adamantyl SCRA                                                | Urine       | UPLC-MS/QToF                                   | Qualitative | Germany     | 2018-2020    | 21        |
| 4F-MDMB-BICA, 4F-MDMB-BINACA, 5F-ABICA amide hydrolysis metabolite, 5F-AB-PINACA, 5F-ADB-PINACA, 5F-cumyl-PEGACLONE, 5F-cumyl-PICA, 5F-MDMB-P7AICA, 5F-MDMB-PICA, 5F-MDMB-PINACA, AB-FUBINACA amide hydrolysis metabolite, AB-CHMINACA, ADB-BINACA, ADB-CHMINACA, ADB-FUBINACA, AMB-4en-PICA, AMB-CHMICA, AMB-FUBICA, cumyl-4CN-B7AICA, cumyl-4CN-BINACA, cumyl-CBMEMACLONE, cumyl-CBMINACA, cumyl-CBMINACA, cumyl-PEGACLONE, EG-018, FUB-144, FUB-APINACA, JWH-081, JWH-122, JWH-210, MDMB-4en-PINACA, MDMB-CHMINACA | Urine       | UHPLC-MS/TQ<sup>b</sup>                        | Qualitative | Germany     | 2018-2020    | 21        |
| 4F-MDMB-BINACA 3,3-dimethylbutanoic acid and 5F-MDMB-PICA 3,3-dimethylbutanoic acid | Urine       | UHPLC-MS/QToF                                   | Qualitative | USA         | 2019          |           |
| 1-benzylpiperazine                                                           | Urine       | GC-MS                                         | Qualitative | Sweden      | 2000-2002     | 68        |
| 5F-ADB, 5F-AMB, AB-CHMINACA, FUB-AMB<sup>c</sup> and MDMB-FUBINACA<sup>c</sup> | Blood, urine | UPLC-MS/TQ                                     | Quantitative | USA         | 2017-201     | 4         |
| 5F-cumyl-PEGACLONE and 5F-cumyl-PEGACLONE<sup>d</sup>                        | Blood, urine | UHPLC-QLIT<sup>e</sup>                        | Quantitative | Germany     | 2019          | 32        |
| ADB-FUBINACA                                                                 | Blood, urine | UHPLC-MS/QToF                                  | Quantitative | USA         | N.A.          | 46        |
| MDMB-4en-PINACA 3,3-dimethylbutanoic acid                                   | Blood, urine | UHPLC-MS/QToF                                  | Qualitative | USA         | 2019          | 48        |
| 4F-MDMB-BINACA and 5F-MDMB-PICA                                              | Blood       | GC-MS and HPLC-MS/QToF                        | Quantitative | Germany     | N.A.          | 40        |
| MDMB-CHMICA                                                                  | Blood       | UPLC-MS/QToF                                   | Qualitative | England     | N.A.          | 43        |
| AM-2201 and JWH-018                                                          | Saliva      | UPLC-MS/QToF                                   | Qualitative | Norway      | N.A.          | 49        |
| Mephedrone and methylone                                                     | Wastewater  | UHPLC-MS/QLIT                                  | Quantitative | Australia   | 2013          | 63        |

<sup>a</sup>Ultra-high performance liquid chromatography-mass spectrometry/linear trap quadrupole-orbitrap.
<sup>b</sup>Ultra-performance liquid chromatography<sup>c</sup>-mass spectrometry/triple quadrupole.
<sup>c</sup>Identified by their butanoic acid conjugated metabolites.
<sup>d</sup>Metabolites.
<sup>e</sup>Ultra-high performance liquid chromatography-mass spectrometry/quadrupole linear ion trap.
Seized NPS were mainly found impregnated into paper or herbal material in the prison setting (Table 2). Literature findings revealed that the mainstay analytical techniques employed for the analysis of non-biological prison samples were liquid chromatography (LC)\(^{20,21,25,27,34,38,41,64}\) or gas chromatography (GC)\(^{5,21,28,31,34,38,41}\) coupled with mass spectrometry (MS), which are regarded as highly discriminatory techniques for forensic analysis of drugs.\(^{73}\) Table 2 shows a prevalence for the use of high-resolution mass spectrometry (HRMS) such as QToF\(^{20,21,27,34,38,41,64}\) and quadrupole-orbitrap.\(^{25}\) In seven studies, GC–MS was employed either as stand-alone\(^{5,31}\) or alongside other techniques.\(^{21,28,34,41}\) The in-field technique IMS was evaluated in two studies screening for SCs in prison.\(^{28,34}\)

Bonds and Hudson developed an analytical workflow for general seized material in prison.\(^{31}\) First, unknown powders were analysed by colorimetric tests while tablets were compared against the TICTAC database, then in some cases further analysed either by IR or GC–MS. Herbal matrices were analysed by GC–MS. Only 15 different SCs in the form of herbal material were detected, and no other NPS were found in these prison seizures.\(^{31}\) Herbal matrices were reported in an additional three studies where extraction was performed using pure methanol\(^{21,28,64}\) or ethanol.\(^{31}\) Some studies reported centrifugation and withdrawal of supernatant\(^{54}\) or filtration of the extracts\(^{28}\) to reduce impurities introduced in the chromatographic column. Ford and Berg (2016) were able to detect a wide range of substances with different polarities in seized herbs using UPLC–MS/QTof with two simultaneous screening methods,\(^{64}\) a "NOIDS screen" (>100 SCs) and "general screen" (>1300 drugs and metabolites). It was more common to see samples containing only one SC\(^{21,28,31,64}\); however, some samples contained multiple SCs. Up to eight SCs were found in one samples by Bonds and Hudson.\(^{31}\) The majority of studies found in Table 2 characterized NPS on paper seized in prison. Ford and Berg were the first to present analytical evidence of NPS smuggled on paper. In this study, as well as Apirakkan et al., sniffer dogs were used initially to detect SCs on paper which were then sent for further analysis.\(^{25,27}\) In general, paper matrices were sampled using areas ranging from 0.70 to 1 cm\(^2\)\(^{25,20,27,28,38,41}\); for example, a biopsy punch was employed by Norman et al. to ensure sampling consistency. Samples were extracted for 5 to 20 min\(^{25,27,38,41}\) either in pure methanol\(^{5,20,25,27,28,38,41}\) or a combination of methanol and dichloromethane (25:75),\(^{38}\) in order to cover compounds with different polarities. To extract substances from paper, one extraction was used in most studies\(^{5,20,25,27,28,38,41}\) McKenzie and co-workers\(^{38}\) spiked paper with known quantities of SCs (i.e., 5F-MDMB-PICA, 4F-MDMB-BINACA, 5F-MDMB-PINACA, AMB-FUBINACA, and AMB-CHMICA) and showed that 94–98% was recovered after one extraction in 25:75 methanol/dichloromethane with approximately 100% recovery when three consecutive extractions were performed. In the case of Haschmi et al., a paper sample was seized from a deceased inmate’s cell who tested positive for 4F-MDMB-BINACA metabolite in urine. Analysis of the paper sample showed no SCs using GC–MS; however, further analysis with the more sensitive HPLC–MS/QTof identified 4F-MDMB-BINACA and 5F-MDMB-PICA.\(^{41}\) This case highlights the importance of determining typical concentrations for NPS and specifically SCs on paper to determine which methods/techniques are the most suitable for these sample types. To this end, McKenzie and co-workers used a combination of two techniques for identification and quantification of SCs infused in paper seized in Scottish prisons between 2018 and 2019.\(^{38}\) This was the first report on SC concentrations in paper samples (\(n = 145\)). The SCs quantified by GC–MS, collected by \(3 \times\) extraction, were the following: 5F-MDMB-PICA (\(n = 59\), \(<0.08 \pm 0.01\) to 0.76 ± 0.11 mg/cm\(^2\) paper); 4F-MDMB-BINACA (\(n = 45\), \(<0.09 \pm 0.01\) to 0.94 ± 0.14 mg/cm\(^2\) paper); 5F-ADB (\(n = 42\), \(<0.05 \pm 0.01\) to 1.17 ± 0.17 mg/cm\(^2\) paper); MDMB-4en-PINACA (\(n = 22\), \(<0.07 \pm 0.01\) to 0.58 ± 0.09 mg/cm\(^2\) paper); AMB-FUBINACA (\(n = 5\), 0.20 ± 0.03 to 1.16 ± 0.17 mg/cm\(^2\) paper); and AMB-CHMICA (\(n = 1\), 0.58 ± 0.09 mg/cm\(^2\) paper).\(^{38}\) Furthermore, concentration mapping showed a variability of 5-fold for AMB-CHMICA across seized paper ranging between 0.47 and 2.38 mg/cm\(^2\)\(^{238}\) demonstrating the inhomogeneity of SCs across paper samples linked to the drying process employed. A study by Caterino et al. evaluated the impact of latent fingerprint detection (i.e., exposure to 1,8-diazafluoren-9-one [DFO] and ninhydrin) on the extraction and detection of SC impregnated paper.\(^{7}\) The presence of four SCs, 4F-MDMB-BUTINACA, 5F-ADB, 5F-MDMB-PICA, and the 2’-indazole isomer of 4F-MDMB-BUTINACA, were successfully identified by GC–MS before and after fingerprint analysis, as well as in the ninhydrin run-off. Although SCs were detected in all three scenarios, quantitative analysis would be helpful to assess the concentration reductions encountered due to this type of processing. In an effort to distinguish SC optical isomers found on paper, Antonides et al. used two chiral columns (i.e., a Phenomenex Lux\(^{2}\) Amylose-1 and Lux\(^{2}\) i-Cellulose-5 [5 \(\mu\)m, 4.6 × 100 mm]) coupled to a HPLC-photo diode array (PDA)/MS–QToF method to analyse 177 SC infused paper samples seized in Scottish prisons between 2018 and 2020.\(^{20}\) SCs were the enantiopure (S)-enantiomer in >89% of the samples, although in 2–16%, the (R)-enantiomer was detected as well. This study highlighted the potential for chiral profiling of chiral valinate and terti-leucinate based SCs to distinguish production batches of drugs for intelligence purposes.

The in-field technique IMS was evaluated in two studies screening for SCs in prison.\(^{28,34}\) Generally, laboratory-based hyphenated techniques are regarded as confirmatory techniques, while in-field techniques are employed as a preliminary test. Quick, minimal, and non-destructive sample preparation makes IMS well-suited for in-field analysis by non-expert users; for example, the analytes were collected by rubbing a Teflon sample trap on the sample’s surface.\(^{28,34}\) Metternich et al. evaluated both simulated and prison casework samples using the IMS IONSCAN600\(^{28}\). The simulated samples
contained mixtures of 5F-ADB and five TdA/prescription only medicine (POM) (100 ng for each compound) concealed in cosmetic and food samples, while 36 casework samples were mainly in herbal and paper form. The IMS identified 5F-ADB in most of the matrices evaluated (i.e., 9 of 11), but failed in highly viscous matrices (e.g., toothpaste or liquid soap). For the casework samples, 12 samples (mainly herbal material) tested positive for SCs which were confirmed by GC–MS analysis. In contrast, Norman et al. focused on the detection of SCs in seized paper samples (n = 392) to evaluate the operational reliability of two Ion Trap Mass Spectrometers (ITMS®), the Rapiscan Itemiser® 3E and 4DN. Sampling was performed on paper of varying sizes which resulted in high trap loading variability. A limited but tailored IMS library, composed of nine “Spice alarm,” was employed to detect the SCs using the reduced mobility (K0) and drift time. The study found that the level of agreement between ITMS® and GC–MS results was 91.1% for the Itemiser® 3E and 92.9% for the Itemiser® 4DN instruments. Reasons for disagreement included both false negative (e.g., no IMS alarm generated for trace or multiple SCs present) and false positive (e.g., Spice, buprenorphine, and cocaine alarms generated by IMS, but not detected by GC–MS) results. The Itemiser® 3E was more suitable for the detection of SCs due to its ability to detect cumyl compounds (cumyl-4CN-BINACA and 5F-cumyl-PGACLONE) compared with the Itemiser® 4DN. The observed LODs (oLOD) were determined for nine SCs and ranged from 0.5 to 100 ng and 5 to 500 ng for the Itemiser® 3E and Itemiser® 4DN (Region 0) instruments, respectively. It was highlighted that variability of the K0 values for the compounds between different instruments could lead to misidentification or false negatives. Reduced selectivity can occur as substances that exhibit a difference <0.025 cm2 V−1 s−1 in their K0 values cannot be discriminated unambiguously, for example, 5F-PB-22 and AB-CHMINACA with K0 values of 0.9995 and 0.9975 cm2 V−1 s−1, respectively. On the other hand, newly emerging SCs with structural similarity to the compounds already in the library can potentially be identified, based on the overlapping K0 values. Nonetheless, IMS has difficulty when detecting more than one analyte in a mixture, where only the analyte with higher peak intensity is detected by the instrument. For example, in a sample containing a mixture of AB-CHMINACA, APINACA, 5F-ADB, MMB-2201, and caffeine, only 5F-ADB was detected. Additionally, the low LOD, in the ng range, could lead to false positives due to cross-contamination, arising from papers collected and stored in the same evidence bag.

3.3.2 Analysis and sample preparation of NPS in biological matrices

In this section, articles including post-mortem analysis of specimens case studies of prisoners admitted to hospital following NPS intake, as well urine, saliva or wastewat analysis carried out on prison samples are presented (Table 3). In general, biological samples were pretreated, before NPS extraction, by the addition of buffers (i.e., acetate, phosphate or carbonate) and/or pH manipulation by addition of sodium hydroxide or trisaminomethane (TRIS HCl) to reduce enzymatic activity and preserve the NPS. The main analytical technique employed for the analysis of biological samples was liquid chromatography coupled with mass spectrometry (LC–MS) or tandem mass spectrometry (MS/MS). Different MS analysers or their combination such as triple quadrupole, quadrupole-linear ion trap, linear trap quadrupole-orbitrap, and quadrupole-linear ion trap were employed. These analyses were all equipped with HRMS-MS capabilities except for the triple quadrupole. Additionally, the use of GC–MS and one immunoassay were also reported.

Urine was the biological matrix most reported for ante-mortem detection of NPS consumed by prisoners. The preference for this matrix can be explained by the low invasiveness of the collection technique, and the longer detection window of drug metabolites (days-weeks), when compared with blood matrices (hours-day). However, urine is susceptible to factors including quantity collected, pH, difference in individual metabolism which may influence the quantitative results. Additionally, urinalysis leads to minimal parent drug detection, while being more useful for the identification of metabolites. For instance, different SCs can undergo different metabolic reactions in the human liver and form the same metabolite, thus making the identification of the exact SC ambiguous, for example, 5F-ADIBICA amide hydrolysis metabolite may result from 5F-ABICA, 5F-AMB-PICA, or 5F-EMB-PICA metabolism. However, in a clinical rather than a forensic context, this is not always disadvantageous as demonstrated by Rook et al., which employed the metabolite 1-adamantylamine as a urine marker to quickly identify adamantyl-type SCs, for example, 5F-AKB-48, AKB-48, and STS-135 in an emergency context. Extraction of the NPS from urine samples was performed by standard techniques such as precipitation, filtration, liquid–liquid extraction (LLE), and solid-phase extraction (SPE) depending on the matrix. Bonds and Hudson employed a reversed-phase SPE (i.e., Agilent Nexus polymer sorbent) and extracted analytes with different polarities such as non-SC NPS, OTC/POM, and TdA. Similarly, a SPE cartridge based on a bimodal non-polar and strong cation exchange (SCX) mechanism (i.e., Agilent Bond Elut Certify cartridge) was also effective at extracting SCs along with other drugs (e.g., cocaine and ampheta-mine-like substances). Lastly, Norman et al. employed a non-polar and anion exchange SPE cartridge (i.e., Agilent Bond Elut Plexa PAX) effective for SCs and their metabolites. In an effort to recover NPS for quantification purposes, β-glucuronidase enzymes were often added to urine samples to hydrolyse glucuronide metabolites back to the parent drug. Rook et al. employed the UPLC-MS/QTof qualitative methods previously described by Ford and Berg for the analysis of non-biological samples. Similar to Ford and Berg, Bonds and Hudson employed simultaneously two screening methods with a UHPLC–MS/LTQ-Orbitrap and a UHPLC–MS/Q-Orbitrap to detect NPS in urine specimens (i.e., a “general screen” and a “SCRA screen,” respectively) to cover a wider range of substances with different polarities, increasing the chance of positive detection. The UHPLC–MS/TQ system, employed for the analysis of urine
samples from German prisons, successfully identified, on full scan, 31 SCs and metabolites, which were then confirmed in multiple reaction monitoring (MRM) mode.\textsuperscript{21} Several studies also utilized a stable isotopically labelled (SIL) IS to correct for analyte loss during sample preparation.\textsuperscript{4,31,68} For example, hydroxypentyl JWH-018-d5. SCs in biological matrices are not usually detected through GC-MS methods\textsuperscript{4} due to low concentration and the requirement of a derivatization step before analysis. In one case, GC-MS was successfully employed to analyse urine samples (i.e., derivatization via fluorinated anhydride) from 11 prisoners for the emerging NPS, 1-benzylpiperazine.\textsuperscript{66} A point of care (POC) test was also trialled for the screening of urine samples from prisons. The “Spice” immunoassay “dip and read” was externally validated on urine samples (n = 514); it gave a positive SC match for only 1.4% of the samples tested versus 20% confirmed by UPLC-MS/MS.\textsuperscript{31} A high number of results (n = 96) were likely false negatives, while 0.2% false positives were recorded. This highlighted limitations in coverage and sensitivity; therefore, the authors did not recommend the use of such immunoassays.\textsuperscript{57} When performing immunoassays, the usefulness of false positives, which may be due to the cross-reactivity of substances present in a sample that have similar characteristics, must be noted.

Blood samples were used in post-mortem\textsuperscript{4,32,40} or antemortem analysis in hospitalized and unresponsive prisoners\textsuperscript{43,46} as it involves a more invasive collection by trained staff. In general blood specimens are more challenging to handle and store due to putrefaction and autolysis processes\textsuperscript{81} especially when post-mortem. Blood analysis enables mainly detection of the parent drug in contrast to urine analysis\textsuperscript{81}; however, it is possible to detect the metabolite in blood as well, for example, MDMB-4en-PINACA 3,3-dimethylbutanoic acid detected in post-mortem femoral blood.\textsuperscript{48} The characteristic and quality (i.e., pH level, presence of clots, and water quantity) of blood specimen is strictly related to the site of blood collection, for example, central, or peripheral. Central blood, due to post-mortem redistribution, contains increased drug levels,\textsuperscript{32} which may compromise exact quantification; hence, analysis of femoral blood is preferable. For example, Giorgetti et al. found a higher quantity of the novel SC 5F-cumyl-PEGACLONE in central (0.22 ng/ml) versus femoral (0.12 ng/ml) blood.\textsuperscript{32} The addition of SIL IS, for example, JWH-200-d5 in this case, was employed for accurate quantification purposes of SCs. This study also highlighted the challenges with the lack of data on post-mortem redistribution and toxic concentration ranges in the assessment of the toxicological significance score of SCs. In contrast, higher concentrations (34–17 ng/ml) of the SC ADB-FUBINACA were detected in the serum of a “body packer” after the containment was compromised.\textsuperscript{46} To target low SC concentrations, Kleis et al.\textsuperscript{40} reported a LC-MS/QTof qualitative screening approach run in auto-MS/MS, a data-independent acquisition (DIA) scan mode in conjunction with a preferred SC list. This was used to identify 5F-MDMB-PICA and 4F-MDMB-BINACA in the femoral blood of an inmate, which were then quantified and found to be 0.14 and 0.48 ng/ml, respectively. In addition, Krotulski et al. also used a DIA scan mode termed MS/MS\textsuperscript{ALL} with SWATH\textsuperscript{6} acquisition which records the MS/MS of every molecule in the sample which led to the detection of MDMB-4en-PINACA metabolite in a forensic toxicological case of an inmate.\textsuperscript{48} A data mining approach which is the retrospective analysis of data files acquired under non-targeted conditions to determine the presence of drugs that were not tested for at the time of first data processing, was also applied to the samples analysed by these authors. Meyyappan et al. employed the same UPLC-MS/QTof qualitative methods previously described by Ford and Berg\textsuperscript{64} and Rook et al.\textsuperscript{35}

Lastly, NPS were also detected in saliva and wastewater. As the need for easy and non-invasive collection of biological specimens is increasing,\textsuperscript{49} Øiestad et al.\textsuperscript{49} validated a screening method for SCs using a commercially available oral fluid collection device. Time to sampling was highlighted as a key factor for the analysis of this matrix, due to the high enzymatic activity in the saliva. However, stability issues were overcome by the addition of a preservative solution in the vial of the collection device made of chlorhexidine digluconate, Tween\textsuperscript{20}, Flag Blue dye and deionized water, followed by storage at 4°C. During the analysis a large ion enhancement up to 6000% was recorded, due to the use of the preservative solution. A diazepam-d5 IS was added during sample preparation, yet was not useful as it eluted earlier in the run, highlighting the importance of accurate selection of IS. This method also offered the advantage of detecting the parent drugs instead of the metabolite; however, the potential for adulteration or contamination should be considered. Wastewater analysis (WWA) was carried out in a small Australian prison to assess drug use and to compare its result to urinalyses.\textsuperscript{53} This approach allowed a daily representation of drugs used by prisoners; for instance, on day 12, 537 mg (3–5 daily doses) of methylene were detected. Mephedrone was also detected but concentrations were below the quantification limit (<0.0001–<0.025 µL/L) of the UHPLC-MS/quadrupole linear ion trap (QLIT) employed. When WWA and urinalyses were compared, no methylene was detected by urinalyses due to the different type of sampling. This highlights the advantage of WWA in gaining a daily picture of the overall use of drugs in contrast to routine urinalyses, which are often targeted. However, it was unfeasible to discern between the prisoner and staff/visitor’s contribution.\textsuperscript{63}

4 | CONCLUSIONS

This study reviewed the NPS reported in prisons, ways and forms in which they are smuggled, and analytical methods used to detect them. SCs were by far the dominant NPS group reported, followed to a lesser extent by synthetic cathinones, synthetic opioids, new benzodiazepines, and stimulants. Specifically, SCs belonging to the last generation subclasses of the tert-leucinate indazole carboxamides (i.e., 4F-MDMB-BINACA and MDMB-4en-PINACA), tert-leucinate indole carboxamides (i.e., 5F-MDMB-PICA), and tert-leucinamide indazole carboxamides (i.e., 5F-ADB) were the most reported in recent findings. The literature suggests that most NPS, in particular SCs, are smuggled via paper and herbal matrices into prison, predominantly
using postal services. For paper samples, one solvent extraction was sufficient for identification via chromatography-mass spectrometry (i.e., LC-HRMS/MS and GC-MS), while SC quantitative studies reported concentrations between 0.05–1.17 mg/cm² providing parameters for further development of in-field methods. In particular, in-field monitoring by sniffer dogs and IMS were able to detect SCs on paper and shows promise for rapid NPS detection on this matrix. However, IMS suffers from reduced selectivity where substances cannot be discriminated unambiguously. 80 Laboratory-based technique, chromatography-mass spectrometry, was most often employed for the analysis of NPS in biological samples (i.e., LC-HRMS/MS) from prison. Whilst detection of the exact NPS in a forensic context is important to gather intelligence; in a clinical/emergency context of decision making, identification of metabolites as being quicker can be more useful. The application of sample mining and data mining approaches to seized and urine samples can help gain a bigger picture of emerging NPS and their metabolites and to determine when a substance first appeared. The authors would like to highlight the following limitations of the study: (I) a particular focus was given to the UK grey literature (e.g., Her Majesty Prison and Probation Services and Prison and Probation Ombudsman reports) and (II) it was not possible to determine NPS trends in prisons overtime due to a lack of detail reported in the available literature (e.g., different seizure years or missing years).

5 | FUTURE WORK

Based on the outcomes of this review, specific areas are suggested for future work. As SCs were smuggled principally via paper and herbal matrices, rapid and accurate in-field analysis of these sample forms would improve real-time decision-making. Due to the evolving market, focus should be given to monitoring effectiveness of current in-field techniques for identifying new emerging SCs. For instance when IMS fails to identify SCs in suspected samples which produce peaks in the typical SC detection range, it should be used in conjunction with a laboratory-based prison drugs monitoring program.24 As a result of the reduced selectivity and inability of IMS to detect more than one substance in a mixture, future research should also focus on other in-field technologies. It should be noted that spectroscopic techniques such as Raman and FTIR, are powerful analytical techniques,29 that can discriminate between NPS in tablet and powder forms, and between NPS isomers. These are also non-destructive and available in handheld technology; however, they struggle with interfering matrices especially if containing a low amount of NPS, such as herbal material,31 paper matrices or tobacco.28 The use of approaches such as surface enhanced Raman spectroscopy (SERS) using minimally invasive sampling methods could be investigated to promote practical application of SCs detection on paper and herbal matrices. Of particular interest is the application of SERS swabs and colloids, embedded with metal nanoparticles to enhance the Raman signal, already employed for the screening of TdA and NPS.82 A methcathinone spectrum was obtained in the study performed by Lee et al. where 23 μg of the analyte was deposited into SERS active films made of hydroxyethylcellulose polymer and aggregated silver nanoparticles. The samples were wiped with a cotton bud wetted then pressed onto a pre-swelled SERS substrate. Conveniently, the film when dry is similar to paper and can be stored for a year and cut to size when needed.83 While Yu et al. designed paper-based inkjet-printed SERS swabs able to collect trace amounts of analyte from large surface areas, which can be concentrated into a small-volume SERS-active region by lateral-flow concentration. The swabs were validated for the detection of 5 μg of heroin and 5 μg of cocaine on glass slides. The measurements show that the technique is quantitative and repeatable across multiple swabs.84 The easy sampling approach similar to IMS could allow rapid yet selective identification of NPS in herbal and paper matrices.

As immunoassays lacked accuracy, there is still a need to develop sensitive, real-time and non-invasive POC testing to screen for SCs in biological samples (i.e., urine and oral fluids) for use in a decision-making context during on-site intoxication and emergencies. The IMS (IONSCAN LS65) with a high pressure injection system85 was proven effective for detecting TdA gamma-hydroxybutyrate (GHB) and gamma hydroxyvalerate (GHV) in synthetic urine at approximately 3 μg/ml, which suggests the method could potentially work for saliva samples. More recently the same instrument was employed for the detection of cocaine in saliva.86 However, their field collection device, based on a cotton swab with an indicator and a molecularly imprinted polymer (MIP) sorbent, was designed to selectively retain cocaine. Therefore, adaptation of such device to retain SCs would be needed. Moreover, fluorescence spectral fingerprinting combined with numerical modelling could be used to identify the likely presence of SCs, as well as provide more specific information on structural class and concentration (~1 μg/ml). This approach can detect both parent and combusted material, and it is practical for detecting SCs in oral fluids.87 All the procedures mentioned in the above studies85–87 could be employed by non-specialized personnel. For the development of new laboratory-based LC-MS detection methods for detection of NPS in biological samples, HRMS incorporating DIA should be preferred, as this will allow the application of sample mining and data mining. While to monitor NPS general trends in prisons and for intelligence purposes, WWA analysis would provide a more representative picture of the overall extent of substance use, compared with MDT. WWA is already used for TdA in Australia and trialled in the United States and Spain.26 This approach compared with MDT is more cost-effective and less invasive. Recently an air monitoring approach, already employed for the detection of NPS88 was evaluated for detection of SCs. Paul et al.89 employed a combination of fixed and mobile sampling units, worn by prison officers, coupled with thermal desorption (TD) sorbent tubes, allowing for multiple location sampling. A two-dimensional gas chromatography (GCxGC)-MS/ToF method was validated for AB-FUBINACA, UR144, MDMB-4en-PINACA, and MDMB-CHMCA; however, these SCs were not found in the collected samples. Therefore further investigation on wide applicability of the technique to detect SCs in prisons should be considered.
REFERENCES

1. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA operating guidelines for the European union early warning system on new psychoactive substances. 2019. doi:10.2810/027404

2. United Nations Office on Drugs and Crime (UNODC). The challenge of new psychoactive substances: a report from the global SMART programme March 2013. Global SMART Programe. Published 2013. Accessed October 14, 2020. https://www.unodc.org/documents/scientific/NPS_Report.pdf

3. Peacock A, Bruno R, Giesv N, et al. New psychoactive substances: challenges for drug surveillance, control, and public health responses. Lancet. 2019;410(10093):1-17. doi:10.1016/S0140-6736(19)32231-7

4. Hvozdovich JA, Chronister CW, Logan BK, Goldberger BA. Case report: synthetic cannabinoid deaths in state of Florida prisoners. J Anal Toxicol. 2019;44(3):298-300. doi:10.1093/jat/bkz092

5. Caterino J, Clark J, Yohannan JC. Analysis of synthetic cannabinoids on paper before and after processing for latent print using DFO and ninhydrin. Forensic Sci Int. 2019;305(110000):1-5. doi:10.1016/j.forsciint.2019.110000

6. User Voice. Spice: the bird killer. What prisoners think about the use of spice and other legal highs in prison. Published 2016. https://www.uservoice.org/wp-content/uploads/2020/07/User-Voice-Spice-The-Bird-Killer-Report-compressed.pdf

7. HM Chief Inspector of Prisons for England and Wales. Annual report 2018–19. 2019. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/814689/hmip-annual-report-2018-19.pdf

8. HM Inspectorate of Prisons. Thematic report by HM Inspectorate of Prisons Changing patterns of substance misuse in adult prisons and service responses. Published 2015. Accessed July 20, 2020. https://www.justiceinspectorates.gov.uk/hmiprisons/wp-content/uploads/sites/4/2015/12/Substance-misuse-web-2015.pdf

9. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). New psychoactive substances in prison service responses. Published 2015. Accessed July 20, 2020. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/669541/9011-phe-nps-toolkit-update-final.pdf

10. Ralphi N, Williams L, Askew R, Norton A. Adding spice to the porridge: the development of a synthetic cannabinoid market in an English prison. Int J Drug Policy. 2017;40:57-69. doi:10.1016/j.drugpo.2016.10.003

11. HM Chief Inspector of Prisons. HM Chief Inspector of Prisons for England and Wales annual report 2019–20. Published 2020. Accessed July 16, 2020. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/927361/hmi-prisons-annual-report-201920.pdf

12. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). High-risk drug use and new psychoactive substances: results from an EMCDDA Trendspotter Study. doi:10.2810/807363

13. Her Majesty’s Prison and Probation Service. Psychoactive substances in prisons—summary of evidence relating to the use of psychoactive substances in prisons. Published 2019. Accessed July 6, 2020. https://www.gov.uk/guidance/psychoactive-substances-in-prisons

14. United Nations Office on Drugs and Crime (UNODC). World drug report 2020 cross-cutting issues: evolving trends and new challenges. Published 2020. Accessed July 20, 2020. https://wdr.unodc.org/wdr2020/field/WDR20_BOOKLET_4.pdf

15. HM Prison & Probation Service. HMPPS annual digest, April 2020 to March 2021. Published 2021. https://www.gov.uk/government/statistics/hmpps-annual-digest-april-2020-to-march-2021

16. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2020 drug use and health consequences. Published 2020. Accessed July 20, 2020. https://wdr.unodc.org/wdr2020/field/WDR20_Booklet_2.pdf

17. HM Inspectorate of Prisons. HM Chief Inspector of Prisons for England and Wales annual report 2013–14. 2014. https://www.justiceinspectorates.gov.uk/hmiprisons/wp-content/uploads/sites/4/2014/10/HMIP_AR_2013-14.pdf

18. Public Health England. New psychoactive substances (NPS) in prisons: A toolkit for prison staff. Published 2017. Accessed September 9, 2020. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/699170/NPS_toolkit-2.pdf

19. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Report on the risk assessment of N-(1-amo-no-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) in the framework of the Council Decision on new psychoactive substances. Publications Office of the European Union, Luxembourg. doi:10.2810/565855

20. Antonides L.H., Cannaert A., Norman C., et al. Shape matters: the application of activity-based in vitro bioassays and chiral profiling to the pharmacological evaluation of synthetic cannabinoid receptor agonists in drug-infused papers seized in prisons. Drug Test Anal. 2020;13(3):628-643. doi:10.1002/dta.2965

21. Norman C, Halter S, Haschimi B, et al. A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: comparing prison and general populations. Drug Test Anal. 2021;13(4):841-852. doi:10.1002/dta.3002

22. United Nations Office on Drugs and Crime. Current NPS threats. Vol II. 2020.

23. Arillotta D, Schifano F, Napoletano F, et al. Novel opioids: systematic web crawling within the e-psychoadsnario. Front Neurosci. 2020;14:1-10. doi:10.3389/fnins.2020.00149

24. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2019: trends and developments. doi:10.2810/191370

25. Apirakkan O, Frinculescu A, Denton H, et al. Isolation and identification of synthetic cannabinoids in alternative formulations or dosage forms. Forensic Chem. 2020;18(100227):1-10. doi:10.1016/j.forc.2020.100227

26. OHagan A, Hardwick R. Behind bars: the truth about drugs in prisons. Forensic Res Criminal Int J. 2017;52(3):00158. doi:10.15406/frcij.2017.05.00158

27. Ford LT, Berg JD. Analytical evidence to show letters impregnated with novel psychoactive substances are a means of getting drugs to inmates within the UK prison service. Ann Clin Biochem. 2018;55(6):673-678. doi:10.1177/0004563218767462

28. Metternich S, Zörntlein S, Schönberger T, Huhn C. Ion mobility spectrometry as a fast screening tool for synthetic cannabinoids to uncover drug trafficking in jail via herbal mixtures. Drug Test Anal. 2019;11(6):833-846. doi:10.1002/dta.2565

29. Harper L, Powell J, Pijl EM. An overview of forensic drug testing methods and their suitability for harm reduction point-of-care services. Harm Reduce J. 2017;14(1):52. doi:10.1186/s12954-017-0179-5

30. Reithlensen M, Kirtley S, Waffenschmidt S, et al. PRISMA-S: an extension to the prisma statement for reporting literature searches in systematic reviews. Syst Rev. 2021;10(39):1-19. doi:10.1186/s13643-020-01542-z

31. Bonds C, Hudson S. North West ‘through the gate substance misuse services’ drug testing project. Published 2015. Accessed July 31,
32. Giorgetti A, Mogler L, Halter S, et al. Four cases of death involving the novel synthetic cannabinoid 5F-Cumyl-PEGACLONE. Forensic Toxicol. 2019;38(2):314-326. doi:10.1007/s11419-019-00514-w

33. Welsh Emerging Drugs & Identification of Novel Substances (WEDINOS). Annual report 1st October 2015-30th September 2016. Published 2016. http://www.wales.nhs.uk/sitesplus/documents/888/WEDINOS Annual Report 2015-16 %28FINAL%29.pdf

34. Norman C, McKirdy B, Walker G, Dugard P, NicDaéid N, McKenzie C. Large-scale evaluation of ion mobility spectrometry for the rapid detection of synthetic cannabinoid receptor agonists in infused papers in prisons. Drug Test Anal. 2021;13(3):644-663. doi:10.1002/dta.2945

35. Rook W, Ford L, Vale A. Four analytically confirmed cases of use of third-generation synthetic cannabinoid receptor agonists incorporating an adamantyl group. Clin Toxicol. 2016;54(6):533-543. doi:10.1080/15563650.2016.1175005

36. European Monitoring Centre for Drugs and Drug Addiction and European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Technical report on the new psychoactive substance methyl 3,3-dimethyl-2-[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl][amino]butanoate (MDMB-4en-PINACA). Lisbon. 2020. https://www.emcdda.europa.eu/system/files/publications/13478/ TR-MDMB-4en-PINACA_Advanced-release.pdf

37. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and Europol. EMCDDA technical report on the new psychoactive substance methyl 2-(1-(4-fluorobutyl)-1H-indole-3-carbonyl)[amino]-3,3-dimethylbutanoate (4F-MDMB-BICA). Published 2020. https://www.emcdda.europa.eu/system/files/publications/13477/TR-4F-MDMB-BICA_Advanced-release.pdf

38. Norman C, Walker G, McKirdy B, et al. Detection and quantitation of synthetic cannabinoid receptor agonists in infused papers from prisons in a constantly evolving illicit market. Drug Test Anal. 2020;12(4):538-554. doi:10.1002/dta.2766

39. Halter S, Haschini B, Mogler L, Auwärter V. Impact of legislation on NPS markets in Germany—the rise and fall of 5F-ADB. Drug Test Anal. 2020;12(6):853-856. doi:10.1002/dta.2786

40. Kies J, Gernerott T, Halter S, et al. The synthetic cannabinoid 5F-MDMB-PICA: A case series. Forensic Sci Int. 2020;314(110410):1-9. doi:10.1016/j.forsciint.2020.110410

41. Haschini B, Mogler L, Halter S, et al. Detection of the recently emerged synthetic cannabinoid 4F-MDMB-BINACA in "legal high" products and human urine specimens. Drug Test Anal. 2019;11(9):1377-1386. doi:10.1002/dta.2666

42. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)-EUROPOL. EMCDDA-Europol joint report on a new psychoactive substance: methyl 2-(1-cyclohexylmethyl)indole-3-carbonyl)[amino]-3,3-dimethylbutanoate (MDMB-CHMICA). doi:10.2810/868403

43. Meyyappan C, Ford L, Vale A. Poisoning due to MDMB-CHMICA, a synthetic cannabinoid receptor agonist. Clin Toxicol. 2016;55(2):151-152. doi:10.1080/15563650.2016.1227832

44. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Report on the risk assessment of 1-(4-Cyanobutyl)-N-(2-phenylprop-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) in the framework of the Council Decision on new psychoactive substances. Publications Office of the European Union, Luxembourg. doi:10.2810/408735

45. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Report on the risk assessment of methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carbonyl][amino]-3,3-dimethylbutanoate (5F-MDMB-PINACA) in the framework of the Council Decision on new psychoactive substances. Publications Office of the European Union, Luxembourg. doi:10.2810/868403

46. Nacca N, Schult R, Loffin R, et al. Coma, seizures, atiroventricular block, and hypoglycemia in an ADB-FUBINACA Body-Trigger. J Emerg Med. 2018;55(6):788-791. doi:10.1016/j.jemermed.2018.09.012

47. European Monitoring Centre for Drugs and Drug Addiction. EMCDDA technical report on the new psychoactive substance methyl 3,3-dimethyl-2-[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl][amino]butanoate (MDMB-4en-PINACA). 2020.

48. Krutoliski AJ, Canneta A, Stove C, Logan BK. The next generation of synthetic cannabinoids: detection, activity, and potential toxicity of pent-4en and but-3en analogues including MDMB-4en-PINACA. Drug Test Anal. 2020;13(2):1-12. doi:10.1002/dta.2935

49. Øiestad EL, Johansen U, Christophersen AS, Karinen R. Screening of synthetic cannabinoids in preserved oral fluid by UPLC-MS/MS. Bioanalysis. 2013;5(18):2257-2268. doi:10.4155/bio.13.182

50. Prisons and Probation Ombudsman Independent Investigation. Prisons and Probation Ombudsman annual report 2016–17. Published 2017. Accessed December 13, 2020. http://www.ppo.gov.uk/app/uploads/2017/07/PPo_Annual-Report-201617_Interactive.pdf

51. HM Chief Inspector of Prisons for England and Wales. HM Chief Inspector of Prisons for England and Wales annual report 2016–17. Published 2017. Accessed August 16, 2020. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/629719/hmip-annual-report-2016-17.pdf

52. Prisons and Probation Ombudsman Independent Investigation. Prisons and Probation Ombudsman annual report 2015–16. Published 2016. Accessed August 19, 2020. http://www.ppo.gov.uk/app/uploads/2016/09/PPo_Annual-Report-201516_WEB_Final.pdf

53. Prisons and Probation Ombudsman Independent Investigation. Prisons and probation ombudsman annual report 2014–15. Published 2015. Accessed September 21, 2020. http://www.ppo.gov.uk/app/uploads/2015/09/PPo_Annual-Report-2014-15_Web-Final.pdf

54. HM Chief Inspector of Prisons for England and Wales. HM Chief Inspector of Prisons for England and Wales annual report 2014–15. Published 2015. Accessed September 9, 2020. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/761589/hmi-prisons-annual-report-2017-18-revised-web.pdf

55. Lloyd C, Page G, McKeagney N, Russell C. Capital depreciation: the lack of recovery capital and post-release support for prisoners leaving the drug recovery wings in England and Wales. Int J Drug Policy. 2019;70:107-116. doi:10.1016/j.drugpo.2019.06.012

56. HM Chief Inspector of Prisons for England and Wales. HM Chief Inspector of Prisons for England and Wales annual report 2017–18. Published 2018. Accessed November 3, 2020. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/761589/hmi-prisons-annual-report-2017-18-revised-web.pdf

57. Blackman S, Bradley R. From niche to stigma—headshops to prison: exploring the rise and fall of synthetic cannabinoid use among young adults. Int J Drug Policy. 2017;40:70-77. doi:10.1016/j.drugpo.2016.10.015

58. HM Inspectorate of Prisons. HM Chief Inspector of Prisons for England and Wales annual report 2015–16. 2016. https://www.justiceinspectorates.gov.uk/hmiprisons/wp-content/uploads/sites/4/2016/07/HMIP_AR_2015-16_web-1.pdf

59. Prisons & Probation Ombudsman. Annual Report 2018–19. 2019.

60. Coraza O, Colocci S, Marrinan S, et al. Novel psychoactive substances in custodial settings: a mixed method investigation on the experiences of people in prison and professionals working with them. Foren Psych. 2020;11:1-10. doi:10.3389/fpsyg.2020.00460

61. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic: an update from the EU Early Warning System. Publications Office of the European Union, Luxembourg. Published 2020. https://www.emcdda.europa.eu/system/files/publications/13464/20205648_TD0320796ENN_PDF_rev.pdf
62. Grace S, Lloyd C, Perry A. The spice trail: transitions in synthetic cannabinoid receptor agonists (SCRAs) use in English prisons and on release. Drugs Educ Prev Policy. 2019;27(4):271-278. doi:10.1080/09697278.2019.1684878

63. Van Dyken E, Lai FY, Thai PK, et al. Challenges and opportunities in using wastewater analysis to measure drug use in a small prison facility. Drug Alcohol Rev. 2016;35(2):138-147. doi:10.1111/dar.12156

64. Ford LT, Berg JD. Analysis of legal high materials by ultra-performance liquid chromatography with time of flight mass spectrometry as part of a toxicity vigilance system: what are the most popular novel psychoactive substances in the UK? Ann Clin Biochem. 2016;54(2):219-229. doi:10.1177/0004563216651646

65. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Report on the risk assessment of N-(1-phenethyl)pyrrolidin-4-yl)-N-phenylacrylamide (acrylofentanyl) in the framework of the Council Decision on new psychoactive substances. Publications Office of the European Union, Luxembourg. doi:10.2810/16112

66. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Report on the risk assessment of methyl 1-[2-phenylethyl]-4-[phenyl (propanoyl)amino]-piperidine-4-carboxylate (carfentanil) in the framework of the Council Decision on new psychoactive substances. Publications Office of the European Union, Luxembourg. doi:10.2810/411341

67. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Report on the risk assessment of N-phenyl-N-[1-[2-phenylethyl]piperidin-4-yl] cyclopropanecarboxamide (cyclopropylfentanyl) in the framework of the Council Decision on new psychoactive substances. Publications Office of the European Union, Luxembourg. doi:10.2810/895612

68. Wikström M, Holmgren P, Ahiner J. A2 (N-Benzylpiperazine) a new drug of abuse in Sweden. J Anal Toxicol. 2004;28(1):67-70. doi:10.1093/jat/28.1.67

69. Abbate V, Schwenk M, Presley BC, Uchiyama N. The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report). Pure Appl Chem. 2018;90(8):1255-1282. doi:10.1515/pac-2017-0605

70. Expert Committee on Drug Dependence-World Health Organisation. SF-PB-22 Critical review report. 2017.

71. Winstock AR, Maier LG, Zhuparits A, et al. Global drug survey (GDS) 2021 key findings report. 2021. https://www.globaldrugsurvey.com/wp-content/uploads/2021/12/Report2021_global.pdf

72. Penfold C, Turnbull P, Webster R. Tackling prison drug markets: an exploratory qualitative study. Home Office. Published 2016. https://www.researchgate.net/publication/237776662_Tackling_Prin Drug_Markets_An_Exploratory_Qualitative_Study

73. SWGDRUG. Scientific working group for the analysis of seized drugs recommedations. 2016. http://www.swgdam.org/

74. Bell V, Leese M. A mixed methods study of increased security measures in a drug recovery prison: Final Report May 2019. 2019.

75. Scotland Government. The Prisons and Young Offenders Institutions (Scotland) Rules 2011.

76. Legislation.gov.uk. The prison rules. 1999. https://www.legislation.gov.uk/uksi/1999/728/contents/made

77. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) technical report on the new psychoactive substance methyl 2-[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (4F-MDMB-BICA). 2020.

78. Antonides LH, Cannaert A, Norman C, et al. Shape matters: the application of activity-based in vitro bioassays and chiral profiling to the pharmacological evaluation of synthetic cannabinoid receptor agonists in drug-infused papers seized in prisons. Drug Testing and Analysis. 2021;13(3):628-643. doi:10.1002/dta.2965

79. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Perspectives on drugs. Synthetic cannabinoids in Europe. Published 2017. https://www.emcdda.europa.eu/publications/pods/synthetic-cannabinoids_en

80. United Nations Office on Drugs and Crime (UNODC). Recommended methods for the identification and analysis of synthetic cannabinoid receptor agonists in seized materials. 2013.26. https://www.unodc.org/documents/scientific/STNAR48_Synthetic_Cannabinoids_ENG.pdf

81. Kerrigan S. Sampling, storage and stability. In: Clarke Analysis of Drug and Poisons. 4th ed. Pharmaceutical Press; 2011:335-356.

82. Yu B, Ge M, Li P, Xie Q, Yang L. Development of surface-enhanced Raman spectroscopy application for determination of illicit drugs: towards a practical sensor. Talanta. 2019;191:1-10. doi:10.1016/j.talanta.2018.08.032

83. Lee WWY, Silversino VAD, Jones LE, et al. Surface-enhanced Raman spectroscopy of novel psychoactive substances using polymer-stabilized Ag nanoparticle aggregates. Chem Commun. 2016;52(3):493-496. doi:10.1039/c5cc07645f

84. Yu WW, White IM. Inkjet-printed paper-based SERS dipssticks and swabs for trace chemical detection. Analyst. 2013;138(4):1020-1025. doi:10.1039/c2an36116g

85. Mercer J, Shakleya D, Bell S. Applications of ion mobility spectrometry (IMS) to the analysis of gamma-hydroxybutyrate and gamma-hydroxyvalerate in toxicological matrices. J Anal Toxicol. 2006;30(8):539-544. doi:10.1093/jat/30.8.539

86. Sorribes-Soriano A, Herrero-Martínez JM, Esteve-Turrillas FA, Armenta S. Molecularly imprinted polymer-based device for field collection of oral fluid samples for cocaine identification. J Chromatogr A. 2020;1633:461629. doi:10.1016/j.chroma.2020.461629

87. May B, Naqi HA, Tipping M, et al. Synthetic cannabinoid receptor agonists detection using fluorescence spectral fingerprinting. Anal Chem. 2019;91(20):12971-12979. doi:10.1021/acs.analchem.9b03037

88. Gent L, Paul R. Air monitoring for illegal drugs including new psychoactive substances: a review of trends, techniques and thermal degradation products. Drug Test Anal. 2021;13(6):1078-1094. doi:10.1002/dta.3051

89. Gent L, Paul R. Air monitoring for synthetic cannabinoids in a UK prison: Application of personal air sampling and fixed sequential sampling with thermal desorption two-dimensional gas chromatography coupled to time-of-flight mass spectrometry. Drug Test Anal. 2021;13(9):1678-1685. doi:10.1002/dta.3101

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher's website.

**How to cite this article:** Vaccaro G, Massariol A, Guirguis A, Kirton SB, Stair JL. NPS detection in prison: A systematic literature review of use, drug form, and analytical approaches. *Drug Test Anal.* 2022;14(8):1350-1367. doi:10.1002/dta.3263